SNY · Sanofi
The AI's read
Refreshing its product line before Dupixent loses patent protection could help Sanofi keep new treatments coming. But the analysts say a purchase could use much of Sanofi's financial room, and no offer is final. These facts do not show a clear change in Sanofi's outlook.